Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -7.9%

Gross margin was -7.9% in Q1 FY2026, down 107.9 pp from a year earlier. On a trailing-twelve-month basis it was 91.2%, down 8.8 pp year over year. Over 3 fiscal years it narrowed by 4.5 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-7.9%-107.9 pp QoQ
Last fiscal yearDec 2025
95.5%-4.5 pp YoY
LTMMar 2026
91.2%-8.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-107.9 pp——
1 year-4.5 pp——
3 years-4.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
95.5%
Year-over-year change
-4.5pp

Gross Margin vs competitors

How ARCT compares with its peers on the latest reported figures

  • ARCT's LTM Mar 2026 gross margin of 91.2% is the 4th highest of the 8 companies compared; the peer median is 89.7%.
  • Its year-over-year change of -8.8 pp is the 5th highest of 7, against a peer median of -1.4 pp.
  • Over three fiscal years its change of -4.5 pp compares with a peer median of +21.4 pp.
ARCT Competitors Peer median
Gross Margin for ARCT and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
ABUSArbutus Biopharma CorporationLTM Mar 2026100.0% +277.5 pp-2.6 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
PRQRProQR Therapeutics N.V.LTM Mar 202689.7% -10.3 pp-17.0 pp
NVAXNovavax, Inc.LTM Mar 202684.6% -2.8 pp+50.1 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
VALNValneva SELTM Mar 202629.5% -17.1 pp+28.5 pp
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ARCT) 89.7%-1.4 pp+21.4 pp

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.